Related Experiment Video

Updated: Mar 30, 2026

Instrumentation of Near-term Fetal Sheep for Multivariate Chronic Non-anesthetized Recordings
14:40

Instrumentation of Near-term Fetal Sheep for Multivariate Chronic Non-anesthetized Recordings

Published on: October 25, 2015

10.0K

Fetal metabolic influences of neonatal anthropometry and adiposity

Jean M Donnelly1, Karen L Lindsay2, Jennifer M Walsh3

  • 1UCD Obstetrics and Gynaecology, School of Medicine and Medical Science, University College Dublin, Dublin, Ireland. jeandonnelly80@yahoo.co.uk.

BMC Pediatrics
|November 12, 2015
PubMed

Insights

Fetal leptin levels in cord blood are a key predictor of neonatal adiposity, independent of other factors. This finding may inform interventions to reduce childhood obesity risk in large for gestational age infants.

Area of Science:

  • Perinatal medicine
  • Neonatal health
  • Endocrinology

Background:

  • Large for gestational age (LGA) infants face higher risks of lifelong obesity and metabolic issues.
  • Understanding neonatal adiposity predictors is crucial for developing antenatal interventions.
  • This study focused on fetal metabolic factors influencing regional neonatal adiposity in women with prior LGA offspring.

Purpose of the Study:

  • To identify fetal metabolic factors predicting regional neonatal adiposity.
  • To analyze the association between fetal leptin and C-peptide with neonatal adiposity markers.

Main Methods:

  • Analysis of data from the ROLO Kids study (derived from the ROLO trial).
  • Comparison of neonatal anthropometry and skinfold measurements with cord blood leptin and C-peptide in 185 infants.
  • Examination of associations between fetal metabolic factors, birthweight, anthropometry, and adiposity markers.

Main Results:

  • Fetal leptin significantly correlated with birthweight, general adiposity, and various anthropometric measurements.
  • Fetal leptin remained a significant predictor of neonatal adiposity after adjusting for gender, maternal BMI, gestational age, and study group.
  • Fetal C-peptide was not significantly associated with neonatal adiposity in the final analysis.

Conclusions:

  • Fetal leptin emerges as a critical predictor of regional neonatal adiposity.
  • Further interventional studies are needed to evaluate the impact of neonatal adiposity on childhood obesity.
  • Investigating interventions to reduce circulating leptin levels may be beneficial for improving neonatal adiposity.
Abstract

More Related Videos

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo12:17

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo

Published on: August 2, 2017

11.4K
Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development05:44

Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development

Published on: May 17, 2024

1.3K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
330
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.5K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
282
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.4K
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
462